Selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound. Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the use of selinexor for the treatment of multiple myeloma and provides an update on the latest data regarding the therapeutic. Highlighted are data from the BOSTON trial (NCT03110562), which investigated selinexor plus bortezomib plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with R/R multiple myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.